New 'One-Shot-Fits-Many' HPV vaccine enters first human tests

NCT ID NCT05208710

Summary

This is a first-in-human safety study of PANHPVAX, a new experimental vaccine designed to prevent infections from many types of cancer-causing human papillomavirus (HPV). The trial will enroll 45 healthy volunteers to test increasing doses of the vaccine, with and without an immune-boosting additive, to see if it is safe and triggers an immune response. Unlike current HPV vaccines that target specific virus types, this new shot aims to provide broader protection against multiple HPV strains linked to cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Department of Clinical Pharmacology and Pharmacoepidemiology

    RECRUITING

    Heidelberg, 69120, Germany

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.